People with type 2 diabetes in England are to get the biggest shake-up of care in a decade, which could see them offered ...

The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, ...

The NHS should move away from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart ...

Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.

New draft guidance from the National Institute for Health and Care Excellence suggests the NHS should move away from a one-size-fits-all approach.

Researchers from Thomas Jefferson University have discovered that combining two diabetes drugs—dapagliflozin and ...

AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Dapagliflozin alongside moderate calorie restricted diet leads to much higher rates of remission from early type 2 diabetes, a study found.

(Balcinrenone + dapagliflozin) is under clinical development by AstraZeneca and currently in Phase II for Proteinuria. According to GlobalData, Phase II drugs for Proteinuria have a 40% phase ...